KalVista Pharmaceuticals, Inc.
KALVNASDAQHealthcare● Active
$26.99
+$0.04(+0.13%)
Market Cap$1.4B
P/E Ratio—
52W High$26.99
52W Low$9.83
KalVista Pharmaceuticals, Inc. (KALV) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · KALV · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2025-04 | 2024-04 | 2023-04 | 2022-04 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $73.62M | $0.00M | $0.00M | $0.00M | $0.00M |
| Cost of Revenue | $6.08M | $0.00M | $86.17M | $0.00M | $0.00M |
| Gross Profit | $67.54M | $0.00M | ($86.17M) | $0.00M | $0.00M |
| Gross Margin %(computed) | 91.75% | — | — | — | — |
| Operating Expenses | |||||
| R&D Expenses | $55.64M | $71.71M | $86.17M | $80.28M | $70.17M |
| G&A Expenses | $0.00M | $116.29M | $54.28M | $30.59M | $26.45M |
| Total Operating Expenses | $239.38M | $188.00M | $54.28M | $110.87M | $96.61M |
| Operating Income | ($171.84M) | ($188.00M) | ($140.44M) | ($110.87M) | ($96.61M) |
| Operating Margin %(computed) | -233.42% | — | — | — | — |
| Interest Income | $8.68M | $6.43M | $3.90M | $2.23M | $1.09M |
| Interest Expense | $19.34M | $5.79M | $0.00M | $0.00M | $0.00M |
| Income Before Tax | ($171.42M) | ($180.05M) | ($135.10M) | ($92.91M) | ($82.34M) |
| Income Tax Expense | ($7.13M) | $3.39M | ($8.45M) | $0.00M | $0.00M |
| Net Income | ($164.29M) | ($183.44M) | ($126.64M) | ($92.91M) | ($82.34M) |
| Net Margin %(computed) | -223.16% | — | — | — | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-3.23 | $-3.69 | $-3.44 | $-3.33 | $-3.36 |
| Wtd Avg Shares | 50.90M | 49.65M | 36.79M | 27.89M | 24.47M |
| EBITDA | ($170.38M) | ($173.33M) | ($134.28M) | ($94.37M) | ($80.75M) |
| EBITDA Margin %(computed) | -231.45% | — | — | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · M
Explore more KalVista Pharmaceuticals, Inc. data
About KalVista Pharmaceuticals, Inc. (KALV) Income Statement
KalVista Pharmaceuticals, Inc. (KALV) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, KALV reported revenue of $0.07B, gross profit of $0.07B (gross margin 91.75%), and net income of ($0.16B) — a net profit margin of -223.16%.
Frequently asked questions
KALV · 4 questionsKalVista Pharmaceuticals, Inc. (KALV) reported revenue of $0.07B for 2025, up —% year-over-year.
KALV revenueKALV salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08